| Similar Articles |
|---|
 |
Bio-IT World
August 18, 2004
John Russell |
A Dozen Sparkling Gems A snapshot of deserving Best Practices Awards entries: Locus Pharmaceuticals... Children's Memorial Hospital, Chicago... XOMA... University of Texas Health Science Center... etc.   |
Bio-IT World
August 2005 |
Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects. |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
Bio-IT World
August 18, 2004
John Russell |
Special Report: 2004: A Best Practices Odyssey Grand Prize Winners: Drug Discovery & Development: Iconix Pharmaceuticals... IT Infrastructure & Informatics: Baylor College of Medicine, Department of Molecular and Cellular Biology Core Lab... etc. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
August 18, 2004
Salvatore Salamone |
Interactive Decision Making SurroMed's core goal is to discover and validate new biomarkers for a broad spectrum of diseases. |
Bio-IT World
August 18, 2004
John Russell |
Curbing a Killer Iconix Pharmaceuticals is working on building biomarkers that can predict toxicity and efficacy. |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Bio-IT World
January 21, 2005 |
Best Practices 2005: Strut Your Stuff Organizations are invited to strut their stuff for Bio*IT World's annual awards program. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Bio-IT World
May 19, 2004
John Russell |
Informatics Black Boxes ... Not! Vertex's chief technical officer, discusses informatics' bad reputation, buying vs. building, open-source tools, and ROI on IT. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
Bio-IT World
August 18, 2004
Mark D. Uehling |
I, Virtual Patient Along with a software company specializing in modeling diseases on the computer, Roche Diagnostics is working on creating a new biomarker for diabetes that could be reduced to a simple blood test. |
Pharmaceutical Executive
July 1, 2005
Ellen H. Julian |
What Pharma Wants From IT Today Indications that compliance and productivity issues reign over information technology (IT) budgets at pharma companies were verified in the 2005 Pharmaceutical Executive/Life Science Insights Information Technology Survey of nearly 850 US pharma companies. |
Pharmaceutical Executive
July 1, 2005
Zaborowski, Hammer & Lawler |
Informatics Rules How global computer systems helped far-flung research centers at Roche work together |
Bio-IT World
March 10, 2003
Spink & Blumenstiel |
Getting IT Right Applying information technology to trials can boost productivity. Here's a strategic framework for going e-clinical. |
Bio-IT World
June 17, 2004
John Russell |
Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine. |
Bio-IT World
March 8, 2005
Patricia Reilly |
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending. |
Bio-IT World
December 15, 2003
Mark D. Uehling |
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
August 2005
Kevin Davies |
Special Report: Bio-IT World Best Practices 2005 Each year, the Best Practices awards program spotlights examples of the most outstanding innovations, technologies, and practices in the drug discovery pipeline. |
Pharmaceutical Executive
May 1, 2007
Weiner & Hovde |
Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks. |
Bio-IT World
November 19, 2004
John Russell |
Sourcebook: Matters of Interpretation Michael O'Connell talks about trends in microarray and mass-spec data analysis and Insightful Corp.'s recent deal with visualization specialist Spotfire. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Bio-IT World
September 2005
Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
Bio-IT World
January 21, 2005
Salvatore Salamone |
A Prescription for Information-Based Medicine TurboWorx president and CEO Jeff Augen not only combines computational and biology expertise, but also has a clear vision of how to advance life science discovery. |
Bio-IT World
March 8, 2005
John Russell |
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow. |
Bio-IT World
March 2006
John Russell |
It's All About the Drugs A conversation with biopharma Organon's executive VP for global research and development highlights how, regardless of the company's enthusiasm for new technology, it is first and foremost interested in pharmacology and medicinal chemistry -- drugs. |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
Bio-IT World
March 2007 |
Briefs Metabolomics Resources... LIMS Collaboration... Biomarker Collaboration... Analysis Update... |
CFO
Scott Leibs & Alix Nyberg |
All Hail the ROI As ROI comes back in vogue, finance executives are reemerginig as technology decision-makers; also, contract management software is booming... |
Bio-IT World
April 16, 2004
Davic Hardison |
The Business Case for Content Management Innovations are allowing bioscience companies to re-address how they manage content and data. |
Bio-IT World
September 2006
John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field. |
Bio-IT World
June 17, 2004
Michael A. Greeley |
A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools. |
Bio-IT World
May 19, 2004
John Russell |
Seeing the Forest and the Trees A tiny clearing in the fog of systems biology. |
Bio-IT World
July 14, 2004
Julia Boguslavsky |
Mass Spec Show and Tell The conference director for Cambridge Healthtech Institute offers highlights from the annual meeting of the American Society for Mass Spectrometry, particularly on mass spec and proteomics. |
